Company news
Immunovant, Inc. (NASDAQ:IMVT) news
Immunovant, Inc. news releases on 6ix. Latest, Aug 24, 2022: Immunovant to Host Investor Webcast to Announce Two New Indications for Batoclimab on September…
Press releases — page 2
Immunovant to Host Investor Webcast to Announce Two New Indications for Batoclimab on September 7, 2022
August 23, 2022
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended June 30, 2022
August 4, 2022
Immunovant Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022
June 7, 2022
Immunovant to Report Fourth Quarter and Full Year 2022 Financial Results on June 8, 2022
June 5, 2022
Immunovant to Present at the H.C. Wainwright Global Investment Conference on May 25th
May 22, 2022
Immunovant to Present at the UBS Global Healthcare Conference on May 23rd
May 18, 2022
Immunovant to Present at LifeSci Partners’ Immunology and Inflammation Symposium on May 10th
May 3, 2022
Immunovant to Host Virtual R&D Day on March 30, 2022
March 27, 2022
Immunovant to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 8, 2022
Immunovant Reports Financial Results for the Quarter Ended December 31, 2021
February 3, 2022
Immunovant Appoints Mark Levine as Chief Legal Officer
January 24, 2022
Immunovant to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 6, 2022
Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022
December 29, 2021
Immunovant to Present at the Stifel 2021 Virtual Healthcare Conference
November 11, 2021
Immunovant Reports Financial Results for the Quarter Ended September 30, 2021
November 4, 2021
Immunovant to Participate in Roivant R&D Day 2021
September 26, 2021
Immunovant Appoints Renee Barnett as Chief Financial Officer
September 14, 2021
Immunovant Reports Financial Results for the Quarter Ended June 30, 2021
August 8, 2021
Immunovant to Report Financial Results for Quarter Ended June 30, 2021
August 5, 2021
Immunovant Receives $200 Million Strategic Investment from Roivant Sciences
August 1, 2021
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter and Fiscal Year Ended March 31, 2021
May 31, 2021
Immunovant Reports Financial Results for the Quarter and Nine Months Ended December 31, 2020
February 15, 2021
Immunovant Announces Voluntary Pause in Clinical Dosing of IMVT-1401
February 1, 2021
Immunovant Appoints Rita Jain Chief Medical Officer And Provides Corporate Update
January 11, 2021
Immunovant Reports Financial Results for the Quarter and Six Months Ended September 30, 2020
November 11, 2020
Immunovant Announces Closing of $200.0 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 3, 2020
Immunovant Announces Pricing of Public Offering
September 1, 2020
Immunovant Announces Positive Topline Results from Multi-Center, Placebo-Controlled Phase 2a Trial of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Myasthenia Gravis
August 24, 2020
Immunovant Appoints Michael Elliott Chief Scientific Officer
August 23, 2020
Immunovant Reports Financial Results for the Quarter Ended June 30, 2020
August 11, 2020
Immunovant Reports Financial Results for the Quarter and Fiscal Year Ended March 31, 2020 and Announces Plans for Phase 3 Registrational Trial of IMVT-1401 in Myasthenia Gravis
June 28, 2020
Immunovant Announces Redemption of Warrants and Achievement of First Earnout Milestone under Share Exchange Agreement
May 13, 2020
Immunovant Announces Closing of $139.4 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 15, 2020
Immunovant Announces Pricing of $121.2 Million Public Offering
April 13, 2020
Immunovant Announces Positive Clinical Results from Ongoing Phase 2a Proof-of-Concept Study of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Thyroid Eye Disease
March 29, 2020
Immunovant Reports Financial Results for the Quarter and Nine Months Ending December 31, 2019
February 13, 2020
Immunovant to Present at the 9th Annual SVB Leerink Global Healthcare Conference
February 9, 2020
Health Sciences Acquisitions Corporation and Immunovant to Host Joint Conference Call for the Investment Community on Friday, October 11, at 8:30am EDT
October 7, 2019
Immunovant to Merge with Health Sciences Acquisitions Corporation, Creating New Publicly Listed FcRn-Focused Company
October 1, 2019